Fruman DA - Search Results

1

PI3Kδ inhibitors in cancer: rationale and serendipity merge in the clinic.

Fruman DA, Rommel C. Fruman DA, et al. Cancer Discov. 2011 Dec;1(7):562-72. doi: 10.1158/2159-8290.CD-11-0249. Epub 2011 Nov 29. Cancer Discov. 2011. PMID: 22586681 Review.

2

ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors.

Kharas MG, Fruman DA. Kharas MG, et al. Among authors: fruman da. Cancer Res. 2005 Mar 15;65(6):2047-53. doi: 10.1158/0008-5472.CAN-04-3888. Cancer Res. 2005. PMID: 15781610 Review.

3

T-cell function is partially maintained in the absence of class IA phosphoinositide 3-kinase signaling.

Deane JA, Kharas MG, Oak JS, Stiles LN, Luo J, Moore TI, Ji H, Rommel C, Cantley LC, Lane TE, Fruman DA. Deane JA, et al. Among authors: fruman da. Blood. 2007 Apr 1;109(7):2894-902. doi: 10.1182/blood-2006-07-038620. Blood. 2007. PMID: 17164340 Free PMC article.

4

Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells.

Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM, Fruman DA. Kharas MG, et al. Among authors: fruman da. J Clin Invest. 2008 Sep;118(9):3038-50. doi: 10.1172/JCI33337. J Clin Invest. 2008. PMID: 18704194 Free PMC article.

5

Fine tuning the immune response with PI3K.

Fruman DA, Bismuth G. Fruman DA, et al. Immunol Rev. 2009 Mar;228(1):253-72. doi: 10.1111/j.1600-065X.2008.00750.x. Immunol Rev. 2009. PMID: 19290933 Review.

6

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor.

Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA, Vu C, Lilly MB, Mallya S, Ong ST, Konopleva M, Martin MB, Ren P, Liu Y, Rommel C, Fruman DA. Janes MR, et al. Among authors: fruman da. Nat Med. 2010 Feb;16(2):205-13. doi: 10.1038/nm.2091. Epub 2010 Jan 13. Nat Med. 2010. PMID: 20072130 Free PMC article.

7

Targeting TOR dependence in cancer.

Janes MR, Fruman DA. Janes MR, et al. Among authors: fruman da. Oncotarget. 2010 May;1(1):69-76. doi: 10.18632/oncotarget.110. Oncotarget. 2010. PMID: 20657741 Free PMC article.

8

Target of rapamycin signaling in leukemia and lymphoma.

Vu C, Fruman DA. Vu C, et al. Among authors: fruman da. Clin Cancer Res. 2010 Nov 15;16(22):5374-80. doi: 10.1158/1078-0432.CCR-10-0480. Epub 2010 Sep 8. Clin Cancer Res. 2010. PMID: 20826559 Review.

9

A lipid kinase cousin cooperates to promote cancer.

Beagle B, Fruman DA. Beagle B, et al. Among authors: fruman da. Cancer Cell. 2011 Jun 14;19(6):693-5. doi: 10.1016/j.ccr.2011.05.020. Cancer Cell. 2011. PMID: 21665142 Free PMC article.

10

PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances.

So L, Fruman DA. So L, et al. Among authors: fruman da. Biochem J. 2012 Mar 15;442(3):465-81. doi: 10.1042/BJ20112092. Biochem J. 2012. PMID: 22364281 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

147 results

Search Page